Literature DB >> 5497794

Distribution and metabolism of L-3-O-methyldopa in rats.

G Bartholini, I Kuruma, A Pletscher.   

Abstract

1. After intraperitoneal administration of L-2-(14)C-3-O-methyldopa ((14)C-O-methyldopa) to rats, the amino-acid was distributed evenly in blood, brain, heart, adipose tissue and liver, whereas it accumulated more in the kidney and the pancreas. (14)C-O-methyldopa showed a biological half-life of about 12-13 h in blood, brain and heart.2. The concentration curve of (14)C-O-methyldopa in brain (after increasing doses of the amino-acid) was linear if measured 2 h after administration, but seemed to reach a plateau at the higher doses if determined after 16 h.3. The concentrations of (14)C-O-methyldopa metabolites (mainly homovanillic acid and 4-hydroxy-3-methoxyphenyllactic acid) were low, except in the kidney, and varied according to the tissue.4. Twenty-four hours after administration of (14)C-O-methyldopa, 33% of the injected radioactivity appeared in the urine. This radioactivity consisted of about 95% of metabolites (probably in the main (14)C-homovanillic acid and (14)C-4-hydroxy-3-methoxyphenyllactic acid) and of 5% of unchanged (14)C-O-methyldopa. In the faeces, 10% of the radioactivity appeared, mainly as metabolic end-products.5. It is concluded that (14)C-O-methyldopa easily penetrates from the blood into various tissues, including brain, and that the majority of the amino-acid undergoes a slow metabolism. The different shape of the concentration curves for (14)C-O-methyldopa in the brain after 2 and 16 h might indicate the presence of two tissue pools of the amino-acid.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5497794      PMCID: PMC1703137          DOI: 10.1111/j.1476-5381.1970.tb10627.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  5 in total

1.  IN-VITRO DECARBOXYLATION OF NEW PHENYLALANINE DERIVATIVES.

Authors:  R FERRINI; A GLAESSER
Journal:  Biochem Pharmacol       Date:  1964-05       Impact factor: 5.858

2.  Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.

Authors:  G Bartholini; A Pletscher
Journal:  J Pharmacol Exp Ther       Date:  1968-05       Impact factor: 4.030

3.  L-dopa-induced accumulation of 3-O-metyldopa in brain and heart.

Authors:  I Kuruma; G Bartholini; A Pletscher
Journal:  Eur J Pharmacol       Date:  1970-05       Impact factor: 4.432

4.  Drug-induced changes of extracerebral dopa metabolism in man.

Authors:  R Tissot; G Bartholini; A Pletscher
Journal:  Arch Neurol       Date:  1969-02

5.  Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans.

Authors:  A Pletscher; G Bartholini; R Tissot
Journal:  Brain Res       Date:  1967-02       Impact factor: 3.252

  5 in total
  5 in total

1.  Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease.

Authors:  J R Bianchine; L Sunyapridakul
Journal:  Drugs       Date:  1973       Impact factor: 9.546

2.  A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.

Authors:  S Grange; N H Holford; T W Guentert
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

3.  Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.

Authors:  F S Messiha; T H Hsu; J R Bianchine
Journal:  J Clin Invest       Date:  1972-02       Impact factor: 14.808

4.  [18F]fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine.

Authors:  E S Garnett; G Firnau; P K Chan; S Sood; L W Belbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

5.  Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.

Authors:  L Rivera-Calimlim
Journal:  Br J Pharmacol       Date:  1974-02       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.